• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Cardiovasc Transl Res . The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hyperte

tetano

Editor, Senior Moderator
J Cardiovasc Transl Res


. 2022 Jan 1.
doi: 10.1007/s12265-021-10147-3. Online ahead of print.
The Effects of ATIR Blocker on the Severity of COVID-19 in Hypertensive Inpatients and Virulence of SARS-CoV-2 in Hypertensive hACE2 Transgenic Mice


Xiaoliang Jiang[SUP] #[/SUP][SUP] 1 [/SUP], Huadong Li[SUP] #[/SUP][SUP] 2 [/SUP], Yong Liu[SUP] #[/SUP][SUP] 3 [/SUP], Linlin Bao[SUP] #[/SUP][SUP] 1 [/SUP], Lingjun Zhan[SUP] #[/SUP][SUP] 1 [/SUP], Hong Gao[SUP] 1 [/SUP], Wei Deng[SUP] 1 [/SUP], Jing Xue[SUP] 1 [/SUP], Jiangning Liu[SUP] 1 [/SUP], Xing Liu[SUP] 1 [/SUP], Junli Li[SUP] 1 [/SUP], Jie Wang[SUP] 1 [/SUP], Shuang Wu[SUP] 2 [/SUP], Mingzhe Yan[SUP] 2 [/SUP], Wei Luo[SUP] 4 [/SUP], Pedro A Jose[SUP] 5 [/SUP], Chuan Qin[SUP] 1 [/SUP], Xiuhong Yang[SUP] 6 [/SUP], Dingyu Zhang[SUP] 2 [/SUP], Zhiwei Yang[SUP] 7 [/SUP]



Affiliations

Abstract

Angiotensin-converting enzyme 2 (ACE2) is required for the cellular entry of the severe acute respiratory syndrome coronavirus 2. ACE2, via the Ang-(1-7)-Mas-R axis, is part of the antihypertensive and cardioprotective effects of the renin-angiotensin system. We studied hospitalized COVID-19 patients with hypertension and hypertensive human(h) ACE2 transgenic mice to determine the outcome of COVID-19 with or without AT1 receptor (AT1R) blocker treatment. The severity of the illness and the levels of serum cardiac biomarkers (CK, CK-BM, cTnI), as well as the inflammation markers (IL-1, IL-6, CRP), were lesser in hypertensive COVID-19 patients treated with AT1R blockers than those treated with other antihypertensive drugs. Hypertensive hACE2 transgenic mice, pretreated with AT1R blocker, had increased ACE2 expression and SARS-CoV-2 in the kidney and heart, 1 day post-infection. We conclude that those hypertensive patients treated with AT1R blocker may be at higher risk for SARS-CoV-2 infection. However, AT1R blockers had no effect on the severity of the illness but instead may have protected COVID-19 patients from heart injury, via the ACE2-angiotensin1-7-Mas receptor axis.

Keywords: AT1 receptor blocker; Angiotensin converting enzyme 2; Coronavirus disease 2019; Hypertension.
 
Back
Top Bottom